Mark Roithmayr is Chief Executive Officer of the Alzheimer’s Drug Discovery Foundation, and his primary focus is securing the resources needed to find effective drugs for Alzheimer's disease. Mr. Roithmayr is a seasoned nonprofit executive with experience in both start-ups and mature organizations. His areas of expertise include strategic planning, fundraising, volunteer development, and brand-building.
Mr. Roithmayr was previously Chief Relationship Officer at the Leukemia and Lymphoma Society. There, he helped launch its venture philanthropy initiative, directed its 56 national chapters, and led annual fundraising of over $200 million. Prior to joining the Leukemia and Lymphoma Society in 2013, he served for seven years as president of Autism Speaks. As that organization's first president, he shepherded its growth from a start-up into the world's largest autism research and advocacy organization. During his tenure, Autism Speaks invested more than $170 million in research, resulting in discoveries about the genetic and environmental factors that lead to autism as well as effective treatments for it. Earlier in his career, Mr. Roithmayr held several executive positions with the March of Dimes. He earned a bachelor's degree in communications at Rowan University.